Drug Type Antibody drug conjugate (ADC) |
Synonyms DB-1310 |
Target |
Mechanism HER3 modulators(Receptor tyrosine-protein kinase erbB-3 modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | Phase 2 | US | 10 Apr 2023 | |
Advanced Malignant Solid Neoplasm | Phase 2 | CN | 10 Apr 2023 | |
Solid tumor | Phase 2 | US | 28 Mar 2023 | |
Metastatic Solid Tumor | IND Approval | CN | 09 Apr 2024 |